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To the editor: 
The human proteins rabenosyn-5 and VPS45 form a complex that plays a key role in early endocytosis1-
4
. Pathogenic variants in VPS45 cause severe congenital neutropenia (SCN) with impaired neutrophil 
function, reticulin fibrosis of the bone marrow, and extramedullary hematopoiesis (OMIM: 615285)5-8. 
Patients with a specific VPS45 variant (p.Glu238Lys) also have intellectual disability and bilateral optic 
nerve hypoplasia5,6. To date, the only evidence of a potential role for RBSN in human disease is the 
report of a homozygous missense variant (p.Gly425Arg) in a patient with intellectual disability, seizures, 
microcephaly, osteopenia, mild reticulin fibrosis of the bone marrow, and transient neutropenia9.  
 
We evaluated three siblings, born to consanguineous parents, for a phenotype of SCN, anemia, 
thrombocytopenia, reticulin fibrosis of the bone marrow, dysmorphic facial features, osteopenia, 
hypertriglyceridemia, hepatomegaly, microphthalmia, and optic nerve hypoplasia (Figure 1 A-E). Bone 
marrow examination revealed trilineage hematopoiesis without maturation arrest (Figure S1). 
Myelofibrosis was documented as early as 4 weeks of age and was progressive and severe (Figures S1 
and S2). The proband (patient VI.2) had complete 46,XY male-to-female sex reversal and died at age 20 
months after multiple infections. At autopsy, she was found to have extensive extramedullary 
hematopoiesis. The other two affected siblings (patients VI.3, and VI.4) are currently ages 9 and 5 years. 
They underwent unrelated-donor bone marrow or stem cell transplantation at 8 and 6.5 months of age, 
respectively. Post-transplantation bone marrow examinations have shown a reduction in myelofibrosis 
(Figure 1F) and their circulating blood counts have remained normal (Figure S3). Both have severe 
intellectual disability, are non-ambulatory and non-verbal. The clinical presentation is detailed in Table 
1, Figures S1-S3, and Table S1. 
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The parents and a fourth sibling (patient VI.5), who is currently seven months of age, have no 
neurologic or ophthalmologic abnormalities. The fourth sibling had transient neonatal thrombocytopenia 
and anemia, and has persistent, mild neutropenia (Figure S4). The mother has had chronic moderate 
thrombocytopenia, an elevated immature platelet fraction, and peripheral blood smear with 
macrothrombocytes among variably-sized platelets. These findings have been interpreted as consistent 
with immune thrombocytopenia. Her CBC is otherwise normal. The father’s CBC is normal.  
 
Whole-exome sequencing on the proband (patient VI.2) revealed a variant (NM_022340.3:c.289G>C; 
NP_001289307.1:p.Gly97Arg) in RBSN, the gene encoding rabenosyn-5, which was homozygous in the 
three affected children, heterozygous in each parent and patient VI.5, and predicted to affect mRNA 
splicing and protein function (Figures S5 and S6A).  
 
To assess splicing, we sequenced cDNA libraries from the proband (patient VI.2) and the father. 
Normally-spliced transcripts were not observed in the proband and represented 45% of transcripts in the 
father. The most common abnormal transcripts had skipping of exon 5 or an alternative exon 5a (Figure 
S7). High-throughput RNA sequencing confirmed these observations and revealed abnormally spliced 
transcripts that retain exon 5 and its neighboring introns (Figure S6B).  
 
Immunoblotting showed an absence of intact rabenosyn-5 in the affected patients (Figure S6C). 
Immunofluorescence staining revealed larger, clustered EEA1-positive endosomes in patient fibroblasts 
compared to controls (Figure S6D). These findings suggest that the absence of intact rabenosyn-5 affects 
the structure and function of early endosomes. 
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Transferrin uptake and recycling assays revealed quantitative and qualitative differences in cells from 
the affected patients compared to those from a healthy control. After 30 minutes of uptake, transferrin 
was localized to a more clustered perinuclear region in cells from the affected patient (Figure S6E). In 
addition, total transferrin accumulation was higher, and the washout phase was delayed, in cells from the 
affected patient (Figure S6F). These findings are consistent with a decreased rate of recycling of the 
transferrin receptor and increased steady-state intracellular accumulation of the ligand in cells harboring 
the RBSN variant. The perinuclear clustering and the increased transferrin accumulation were reversed in 
cells transfected with a version of the human RBSN gene that does not have the variant (Figure S8).  
 
Our observations suggest that RBSN loss of function causes a severe syndromic form of congenital 
myelofibrosis, and they confirm that rabenosyn-5 plays a vital role in human development and 
hematopoiesis. The mechanisms by which RBSN loss of function leads to hematologic and 
developmental abnormalities are unknown. As previously suggested for VPS45, the neutropenia may 
result from apoptosis induced by the toxic effects of impaired endosomal trafficking5,7. It is important to 
note, however, that other congenital disorders associated with increased neutrophil apoptosis, such as 
pathogenic variants in ELANE, do not also result in congenital myelofibrosis. Thus, additional factors 
must be at play. One hypothesis is that the myelofibrosis results from impaired trafficking of α-granules 
and their release from megakaryocytes, resulting in a pro-inflammatory, profibrotic response. Also, 
given that RBSN loss of function is predicted to result in a reduction of β1 integrin expression at the cell 
surface, as observed for VPS45 deficiency5, it is tempting to speculate that the optic pathway and other 
central nervous system effects are the result of abnormal axonal transport of integrin transmembrane 
proteins during development. 
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 The phenotypic overlap between our patients and those with mutation affecting VPS455-8 suggests the 
existence of a distinct disorder of early endocytosis caused by pathogenic variants in the genes encoding 
either member of the rabenosyn-5/VPS45 complex. SCN without maturation arrest, reticulin fibrosis of 
the bone marrow, and extramedullary hematopoiesis appear to be the hallmarks of the disease. Anemia 
and thrombocytopenia in our patients were variable and exacerbated by infection and progressive 
hepatosplenomegaly (Table S1 and Figure S3). Long-term survival without substantial hematologic or 
infectious complications was possible after bone marrow or stem cell transplantation, suggesting the 
hematopoietic defect is intrinsic to hematopoietic stem and progenitor cells, although a transferable 
factor from the transplanted cells to the bone marrow cannot be excluded. The neurologic and 
ophthalmologic abnormalities in the surviving patients have remained stable. Other concordant features 
in our patients include facial dysmorphism, abnormal bone development, and hypertriglyceridemia. The 
only sibling homozygous for the RBSN variant who had a 46,XY chromosome complement also had a 
disorder of sex development. This appears to be part of the syndrome, and we hypothesize that it could 
be the result of ineffective endocytosis of sex hormones in utero, as has been observed in animal 
models10. Confirmation will require additional cases of 46,XY individuals with loss-of-function RBSN 
variants.  
 
The mother’s hematologic abnormality is consistent with immune thrombocytopenia. This could explain 
the transient neonatal thrombocytopenia in the heterozygous sibling (patient VI.5), but it would not 
explain his transient anemia and persistent, mild neutropenia. It is certainly possible that the hematologic 
manifestations in these two individuals represent a milder phenotype caused by the RBSN variant in 
heterozygous state.  
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The structural and phenotypic effects of the variant we report are considerably more severe than those of 
the previously reported RBSN variant (p.Gly425Arg)9. In that patient, intact rabenosyn-5 was detected 
by immunoblot, the sub-cellular localization of the protein by immunofluorescence staining was normal, 
and transferrin endocytosis and recycling assays showed a significantly enhanced rate of recycling 
suggestive of a gain-of-function effect. However, the phenotypic overlap with our patients suggests that 
the p.Gly425Arg variant is also pathogenic, leading to a milder phenotype within the same spectrum. 
Therefore, pathogenic RBSN variants, in homozygous or heterozygous state, should also be considered 
in cases of unexplained transient neutropenia, particularly when neurologic abnormalities and/or 
myelofibrosis are also present. 
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Figure Legend 
Figure 1. Family pedigree and phenotypic features of the patients.  
A, Family pedigree indicating consanguinity. Filled symbols represent affected individuals (patients 
VI.2, VI.3, VI.4).  
B, Photographs of patient VI.2 at 11 months, patient VI.3 at 9 years 2 months, and patient VI.4 at 4 
years 11 months. Note microphthalmia, beaked nose, and prominent columella. Consent for the 
publication of images was provided by the patients’ parents. 
C, Absolute neutrophil count over time for the three patients. Shaded blue represents the normal 
reference range based on age. The upper limit of normal in the newborn period in our laboratory is 
23.5x100/uL, which is above the range depicted (*). HSCT: Hematopoietic stem cell transplantation. 
BMT: Bone marrow transplantation. DOD: Date of death. 
D, Brain MRI of patient VI.3 at 9 months of age. Note supratentorial volume loss involving the white 
greater than the gray matter, ex vacuo ventricular enlargement, and optic nerve hypoplasia. 
E, Bone marrow biopsy for patient VI.3 at 33 days of age. Reticulin stain, 200x magnification. Note 
moderate to severe reticulin fibrosis. Trichrome staining for collagen fibers was not performed.  
F, Bone marrow biopsy for patient VI.3 at 20 months of age, one year after bone marrow 
transplantation. Reticulin stain, 200x magnification. Note the reduction in reticulin fibrosis to mild and 
focal. Trichrome staining for collagen fibers was negative (data not shown).  
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Table 1. Clinical, imaging, and histopathologic findings in three patients with a pathogenic RBSN variant  
 
 
 
Patient VI.2 Patient VI.3 Patient VI.4 
Phenotype Female Female Female 
Chromosomes 46,XY 46,XX 46,XX 
CMA Normal (BG v.5 and 400,000 oligonucleotide 
research array) 
Normal (BG v.6.4) Normal (BG v.8.3) 
Growth 11 m: Ht: 25%; Wt: 75%; OFC: 25-50% 9 y 2 m: Ht: <1%, Wt:  76%, OFC: 18% 4 y 11 m: Ht: <1%, Wt: 57%, OFC: 5% 
Facial features Narrow bi-temporal diameter, metopic 
prominence, sloping forehead, upslanting 
palpebral fissures, epicanthal folds, bulbous nose, 
depressed nasal tip 
Prominent nasal bridge, low set, posteriorly 
rotated ears, retromicrognathia, high-arched 
palate 
Bitemporal narrowing, tubular nose, prominent 
columella 
Hematologic  SCN transiently responsive to intermediate-dose 
filgrastim, PB NRBCs, progressive anemia and 
thrombocytopenia, hypercellular bone marrow 
with severe reticulin fibrosis and myeloid 
hyperplasia, extramedullary hematopoiesis (liver, 
spleen, kidneys, lymph nodes) on PME 
SCN without maturation arrest, refractory to 
filgrastim, transfusion-dependent anemia, 
variable thrombocytopenia including at birth and 
with infection, PB NRBCs, normocellular bone 
marrow with moderate to severe reticulin fibrosis 
and maturing trilineage hematopoiesis 
SCN refractory to filgrastim, moderate anemia at 
birth (variably present subsequently), PB 
NRBCs, hypercellular bone marrow with 
moderate to severe reticulin fibrosis and maturing
trilineage hematopoiesis 
Ophthalmologic Poor visual response, microphthalmia, 
hypoplastic irides, microcornea, 
blepharophimosis, absent retinal vessels, aplastic 
optic nerves 
Poor visual response, microphthalmia, 
microcornea, blepharophimosis, aplastic optic 
nerves 
Poor visual response, microphthalmia, aniridia 
with iris coloboma, blepharophimosis, dysplastic 
optic nerves, absent retinal vessels 
Neurologic Increased muscle tone in the lower extremities, 
DTRs 2+, poor head control 
Increased muscle tone in the four extremities, 
DTRs 3+, normal EEG  
Joint restriction, hypotonia, diminished strength, 
muscle atrophy, normal DTRs 
Brain MRI Prominent supratentorial ventricles, sulci, and 
cisterns, widened sylvian fissures, thin corpus 
callosum, cerebral atrophy, severe optic nerve 
and chiasm hypoplasia, diffuse expansion of 
diploic calvarial marrow space 
Perinatal intraparenchymal and subarachnoid 
hemorrhages. Supratentorial volume loss, thin 
corpus callosum, mild myelin maturation delay. 
Hypoplasia of the optic nerve, chiasm, and optic 
tract. Bone enhancement likely related to 
myelofibrosis 
N/A 
Respiratory Tracheomalacia Tracheomalacia Normal 
Cardiovascular Mild cardiomegaly on PME Small PDA, redundant atrial septum Small PFO, small secundum ASD 
Gastrointestinal Gastrostomy feeding only, GE reflux, 
hepatosplenomegaly with extramedullary 
hematopoiesis on PME. Accessory spleen 
Gastrostomy feeding only, mild esophageal 
dysmotility, hepatomegaly likely related to 
extramedullary hematopoiesis 
Gastrostomy feeding only, hepatomegaly likely 
related to extramedullary hematopoiesis 
Orthopedic Osteopenia, congenital hip dysplasia. Tapered 5th 
finger 
Osteopenia, femur fracture, bilateral hip 
dysplasia, clinodactyly, delayed bone age (2-3 y), 
advanced bone age (6-7 y) 
Delayed bone age (-3 SD below mean), bilateral 
hip dysplasia 
Genitourinary Hypoplastic labia minora and majora, 
underdeveloped genital tubercle, anteriorly 
placed anus. Streak gonads, uterine didelphys, 
and double vagina on PME. Nephromegaly with 
extramedullary hematopoiesis on PME 
Nephromegaly, likely related to extramedullary 
hematopoiesis 
Normal 
Endocrine Mild adrenal cortical lipid depletion and pituitary 
hypoplasia on PME, elevated FSH and LH for 
age, normal testosterone   
Elevated FSH for age. Normal 
Audiological Bilateral mild to moderate high-frequency 
sensorineural hearing impairment 
Normal N/A 
Immunologic Frequent infections (Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia, Candida 
albicans, influenza A virus, respiratory syncytial 
virus) 
Normal Ig G, A, M, and E. Normal CH50 activity. 
Normal numbers and ratios of CD4+ and CD8+ T 
cells and CD19+ B cells. NK cells and 
CD4+/CD45RA+ naïve T cells increased in 
absolute number, normal ratio.  CD4+/CD45RO+ 
memory cells low in absolute number and ratio 
Frequent urinary tract infections 
Metabolic Hypertriglyceridemia (249-335 mg/dL) Hypertriglyceridemia (155-1086 mg/dL) Hypertriglyceridemia (176-296 mg/dL) 
Development/ 
Cognition 
Global developmental delay 9 y: Severe intellectual disability, non-verbal, 
non-ambulatory 
5 y: Severe intellectual disability, non-verbal, 
non-ambulatory 
 
CMA: Chromosomal microarray analysis. BG: Baylor Genetics Laboratory. SCN: Severe congenital neutropenia. PB 
NRBCs: Peripheral blood nucleated red blood cells. N/A: Not assessed. m: Months of age. y: Years of age. Ht: Height. 
Wt: Weight. OFC: Occipital frontal circumference. DTRs: Deep tendon reflexes. EEG: Electroencephalogram. PME: 
Postmortem examination. PDA: Patent ductus arteriosus. PFO: Patent foramen ovale. ASD: Atrial septal defect; GE: 
Gastroesophageal. SD: Standard deviations. 
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